Janux Therapeutics

Oncology is, by far, the most lucrative market within biopharma, with Evaluate 2030 sales predictions of more than twice that of the next therapeutic area. In this contested and increasingly granular

Oncology is, by far, the most lucrative market within biopharma, with Evaluate 2030 sales predictions of more than twice that of the next therapeutic area. In this contested and increasingly granular

Last year was far from vintage for the biotech sector in terms of stock performance: the S&P Biotechnology Select Industry Index rose by only 3% in 2024, and lagged far behind the 25% achieved by

Vir Biotechnology’s move from focusing solely on antiviral drugs to incorporating oncology into its pipeline has shown early signs of potentially paying off as the company announced safety and efficac